Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme

Volume: 123, Issue: 1, Pages: 98 - 105
Published: Jul 23, 2018
Abstract
Objective To report the safety and efficacy results of patients enrolled in the Italian Nivolumab Renal Cell Cancer Expanded Access Programme. Patients and Methods Patients with metastatic renal cell cancer (mRCC) previously treated with agents targeting the vascular endothelial growth factor pathway were eligible to receive nivolumab 3 mg/kg once every 2 weeks. Patients included in the analysis had received ≥1 dose of nivolumab and were...
Paper Details
Title
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme
Published Date
Jul 23, 2018
Journal
Volume
123
Issue
1
Pages
98 - 105
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.